cigna glp-1 2025 will stop covering weight-loss drugs including Wegovy and Zepbound in its employee health plan effective July 1, according to Reuters Cigna (CI) Faces Cuts in
Description
### Funding Statement SDL and AC were supported by the National Science Foundation (Grant Nos.\ CAREER DMS-1944574 and DMS-2325258) ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained

The daily pill, called Foundayo, is the second oral GLP-1 product to reach the market over the past few months.

Here's the safety framework, the boxed-warning context, and where PlexusDx oral protocols fit

Explore the CDMO opportunities in the new Metabolic Economy today.
